Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Real-time Estimate Cboe BZX
Other stock markets
 14:56:47 16/05/2024 BST 		5-day change 1st Jan Change
3.445 USD -1.01% Intraday chart for Relmada Therapeutics, Inc. -8.95% -16.43%
05-08 Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08 Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023
CI
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Relmada Therapeutics, Inc. Enters into Amendment No.2 to the License Agreement
CI
Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive Disorder
CI
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive Disorder
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Relmada Therapeutics Says Drug Candidate for Major Depressive Disorder Gets FDA Fast-Track Designation
MT
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
CI
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
CI
Relmada Therapeutics Q4 Loss Widens
MT
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse Potential
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. News Relmada Therapeutics, Inc.
  5. Highlights